BREAKING NEWS: Biolex Presents Phase 2B Results at EASL Showing Reduced Rates of Depression in HCV Patients Treated with Locteron®
Poster Presented at EASL
Biolex Presents Final Phase 2B Results at EASL Highlighting Tolerability Advantages of Locteron® in Treatment of HCV Poster Presented at EASL
Biolex to Present Final Phase 2B Results at EASL for Locteron® Next-Generation Controlled-Release Interferon for HCV
